Tin tức & Cập nhật
Xem bài viết Gan
Xem
Carvedilol reduces decompensation, death in cirrhosis patients with hypertension
Long-term treatment with carvedilol lowers the risk of decompensation of cirrhosis and improves survival in compensated patients with clinically significant portal hypertension (CSPH), reports a study.
Carvedilol reduces decompensation, death in cirrhosis patients with hypertension
12 Oct 2022
Liver stiffness, but not fatty liver disease, linked to atrial fibrillation
Fatty liver disease does not seem to contribute to prevalent or incident atrial fibrillation (AF), but higher liver stiffness does, particularly among individuals without steatosis, reports a recent study.
Liver stiffness, but not fatty liver disease, linked to atrial fibrillation
11 Oct 2022
HBV elimination goals set by WHO not attainable, experts say
Current efforts to eradicate hepatitis B virus (HBV), including vaccination, screening, and treatment strategies, do not seem enough to achieve the elimination goals set by the World Health Organization (WHO), suggests a recent study.
HBV elimination goals set by WHO not attainable, experts say
11 Oct 2022
HBsAg seroclearance tied to lower recurrence risk of HBV-related hepatocellular carcinoma
Hepatitis B surface antigen (HBsAg) seroclearance appears to reduce the risk of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) late recurrence among patients who underwent curative liver resection, results of a Korea study have shown.
HBsAg seroclearance tied to lower recurrence risk of HBV-related hepatocellular carcinoma
10 Oct 2022
Intensive weight-loss does not improve outcomes in obese NAFLD patients
An intensive weight-loss intervention has failed to substantially improve the treatment outcomes among obese patients with nonalcoholic fatty liver disease (NAFLD), reports a recent study.
Intensive weight-loss does not improve outcomes in obese NAFLD patients
22 Sep 2022
Vebicorvir plus Nrtl safe, well tolerated in patients with chronic HBV infection
Treatment with vebicorvir (VBR) plus nucleos(t)ide reverse transcriptase inhibitors (NrtIs) among virologically suppressed patients with chronic hepatitis B virus (HBV) is well tolerated and has a favourable safety profile, according to a 24-week study.
